Skip to main content

Advertisement

SpringerLink
Log in

The activity of azithromycin in animal models of infection

  • Review
  • Published:
European Journal of Clinical Microbiology and Infectious Diseases Aims and scope Submit manuscript

Abstract

High and prolonged tissue levels accompanied by low serum concentrations are a feature of azithromycin, an azalide antibiotic. It has a broad spectrum of activity against gram-positive and gram-negative microorganisms and several intracellular pathogens. A number of animal models of localised infection have been developed which demonstrate that the efficacy of azithromycin correlates with its extravascular pharmacokinetics and not with blood levels. In many instances, because of high tissue bioavailability, azithromycin has better in vivo efficacy than comparative agents, despite a similar or higher minimum inhibitory concentration. Additionally, the extravascular kinetics of azithromycin are associated with bactericidal activity against pathogens such asStaphylococcus aureus, Streptococcus pneumoniae andEscherichia coli. Intracellular pathogens are susceptible to azithromycin and it is believed that the agent penetrates and remains within host cells infected by organisms includingMycobacterium avium, Legionella pneumophila andBorrelia burgdorferi. This paper reviews the in vivo efficacy of azithromycin and standard agents in animal models of infection, especially those involving intracellular pathogens.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Girard AE, Girard D, English AR, Gootz TD, Cimochowski CR, Faiella JA, Haskell SL, Retsema JA: Pharmacokinetics and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution. Antimicrobial Agents and Chemotherapy 1987, 31: 1948–1954.

    PubMed  Google Scholar 

  2. Girard AE, Girard D, Retsema JA: Correlation of extravascular pharmacokinetics of azithromycin with in vivo efficacy in models of localized infection. Journal of Antimicrobial Chemotherapy 1990, 25, Supplement A: 61–71.

    PubMed  Google Scholar 

  3. Girard AE, Girard D, Retsema JA: Correlation of the impressive extravascular pharmacokinetics of azithromycin with in vivo efficacy in models of localized infection. Journal on Chemotherapy of Infectious Diseases and Malignancies 1989, 1, Supplement 1: 404.

    Google Scholar 

  4. Retsema JA, Girard AE, Girard D, Milisen WB: Relationship of high tissue concentrations of azithromycin to bactericidal activity and efficacy in vivo. Journal of Antimicrobial Chemotherapy 1990, 25, Supplement A: 83–89.

    Google Scholar 

  5. Chan KH, Swarts JD, Doyle WJ, Tanpowpong K, Kardatzke DR: Efficacy of a new macrolide (azithromycin) for acute otitis media in the chinchilla model. Archives of Otolaryngology — Head and Neck Surgery 1988, 114: 1266–1269.

    PubMed  Google Scholar 

  6. Retsema JA, Girard AE, Schelkly W, Manousos M, Anderson M, Bright G, Borovoy R, Brennan L, Mason R: Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms. Antimicrobial Agents and Chemotherapy 1987, 31: 1939–1947.

    PubMed  Google Scholar 

  7. Yourassowsky E, van der Linden MP, Lismont MJ, Crokaert F, Glupczynski Y: Rate of bactericidal activity forBranhamella catarrhalis of a new macrolide, CP-62,993, compared with that of amoxicillin-clavulanic acid. Chemotherapy 1988, 34: 191–194.

    PubMed  Google Scholar 

  8. Gladue RP, Bright GM, Isaacson RE, Newborg MF: In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection. Antimicrobial Agents and Chemotherapy 1989, 33: 277–282.

    PubMed  Google Scholar 

  9. Schwab JC, Mandell GL: The importance of penetration of antimicrobial agents into cells. Infectious Disease Clinics of North America 1989, 3: 461–467.

    PubMed  Google Scholar 

  10. Wildfeuer A, Laufen G, Müller-Wening D, Haferkamp O: Interaction of azithromycin and human phagocytic cells. Uptake of the antibiotic and the effect on the survival of ingested bacteria. Arzneimittel-Forschung 1989, 39: 755–758.

    PubMed  Google Scholar 

  11. Inderlied CB, Kolonoski PT, Wu M, Young LS: In vitro and in vivo activity of azithromycin (CP 62,993) against theMycobacterium avium complex. Journal of Infectious Diseases 1989, 159: 994–997.

    PubMed  Google Scholar 

  12. Inderlied CB, Kolonoski PK, Wu M, Young LS: Azithromycin: an effective therapeutic agent for disseminatedMycobacterium avium infection in the beige mouse. Annals of Clinical and Laboratory Sciences 1988, 18: 413–414.

    Google Scholar 

  13. Fitzgeorge RB, Featherstone ASR, Baskerville A: Efficacy of azithromycin in the treatment of guinea pigs infected withLegionella pneumophila by aerosol. Journal of Antimicrobial Chemotherapy 1990, 25, Supplement A: 101–108.

    PubMed  Google Scholar 

  14. Johnson RC, Kodner C, Russell M, Duray PH: Experimental infection of the hamster withBorrelia burgdorferi. Annals of the New York Academy of Sciences 1988: 258–263.

  15. Johnson RC, Kodner C, Russell M, Girard D: In vitro and in vivo susceptibility ofBorrelia burgdorferi to azithromycin. Journal Antimicrobial Chemotherapy 1990, 25, Supplement A: 33–38.

    Google Scholar 

  16. Lukehart SA, Fohn MJ, Baker-Zander SA: Efficacy of azithromycin for therapy of active syphilis in the rabbit model. Journal of Antimicrobial Chemotherapy 1990, 25, Supplement A: 91–99.

    Google Scholar 

  17. Araujo FG, Guptill DR, Remington JS: Azithromycin, a macrolide antibiotic with potent activity againstToxoplasma gondii. Antimicrobial Agents and Chemotherapy 1988, 32: 755–757.

    PubMed  Google Scholar 

  18. Araujo FG, Remington JS: Further studies on the activity of azithromycin (CP-62,993) againstToxoplasma gondii. Journal on Chemotherapy of Infectious Diseases and Malignancies 1989, 1, Supplement 1: 411.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Genetics and Microbiology, University of Geneva Medical School, 9 Champel Avenue, 1211, Geneva 4, Switzerland

    J. C. Pechère

Authors
  1. J. C. Pechère
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pechère, J.C. The activity of azithromycin in animal models of infection. Eur. J. Clin. Microbiol. Infect. Dis. 10, 821–827 (1991). https://doi.org/10.1007/BF01975834

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01975834

Keywords

Search

Navigation